Volk, Timo http://orcid.org/0000-0001-9388-042X
Warnatz, Klaus
Marks, Reinhard
Urbach, Horst
Schluh, Gisela
Strohmeier, Valentina
Rojas-Restrepo, Jessica
Grimbacher, Bodo
Rauer, Sebastian
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GR1617/14-1/iPAD; SFB1160/2_B5; RESIST–EXC 2155–Project ID 390874280; and CIBSS–EXC-2189–Project ID 390939984), SFB1160 TP A04)
Bundesministerium für Bildung und Forschung (GAIN 01GM1910A)
Universitätsklinikum Freiburg
Article History
Received: 13 May 2021
Accepted: 21 June 2021
First Online: 1 July 2021
Declarations
:
: Declare no conflict of interest wrt the content of this manuscript.
: Not applicable.
: All patients received pembrolizumab on a compassionate-use basis after informed consent was obtained.
: All patients, guardians or next of kin have gave written informed consent for publication.